ALPINE GROUP PARTNERS, LLC.
ALPINE GROUP PARTNERS, LLC. filed a Q1 report for ULTRAGENYX PHARMACEUTICAL INC. on July 20, 2026, reporting $40,000 in lobbying income.
Lobbying for ULTRAGENYX PHARMACEUTICAL INC. · Biopharma company developing treatments for rare and ultra-rare diseases.
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)